10-Q/A: BioNexus Gene Lab Corp. Files Amended Quarterly Report Due to SEC Comment

BioNexus Gene Lab Corp. has filed an amendment to its quarterly report to address a comment from the SEC regarding the effectiveness of its disclosure controls and procedures.

Summary

• BioNexus Gene Lab Corp. filed an amendment to its original quarterly report for the period ended June 30, 2023.
• The amendment was made in response to a comment letter from the Securities and Exchange Commission (SEC).
• The sole purpose of the amendment is to restate Part 1, Item 4, which pertains to Controls and Procedures.
• The company's management concluded that their disclosure controls and procedures were not effective as of June 30, 2023.
• This ineffectiveness was due to the use of the term 'capable' in the original filing, which is not compliant with Item 307 of Regulation S-K.
• There were no changes to the company's financial statements as a result of this amendment.
• The company has 17,698,549 shares of common stock outstanding as of August 14, 2023.

Sentiment

Score: 3

Explanation: The document highlights a deficiency in internal controls, which is a negative signal for investors. The need for an amendment also suggests potential issues with the company's reporting processes.

Negatives

• The company's disclosure controls and procedures were not effective as of June 30, 2023.
• The original filing used non-compliant terminology regarding controls and procedures.

Risks

• The company's ineffective disclosure controls and procedures could lead to future issues with financial reporting.
• The need to amend the report indicates potential weaknesses in the company's internal controls.

Management Comments

• Management concluded that the company's disclosure controls and procedures were not effective as of June 30, 2023.
• The CEO, Su-Leng Tan Lee, certified the report and the effectiveness of the controls.

Industry Context

This type of amendment is not uncommon when companies receive comments from the SEC regarding their filings, particularly around internal controls and procedures. It highlights the importance of adhering to regulatory guidelines.

Comparison to Industry Standards

• Companies are expected to maintain effective disclosure controls and procedures as per SEC regulations.
• The need for an amendment suggests that BioNexus Gene Lab Corp.'s controls were not up to par with industry standards at the time of the original filing.
• Other companies in the biotechnology sector are expected to have robust internal controls to ensure accurate financial reporting.

Stakeholder Impact

• Shareholders may be concerned about the effectiveness of the company's internal controls.
• The company's reputation may be negatively impacted by the need for an amendment.

Key Dates

Keywords

disclosure controls, internal controls, SEC, amendment, quarterly report, financial reporting, compliance, Bionexus Gene Lab Corp